PRMT5/EGFR-IN-1

• UNSPSC Description:

  PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual PRMT5/EGFR inhibitor, with IC50s of 15.47 and 19.31 μM, respectively. PRMT5/EGFR-IN-1 exhibits antiproliferative activity against A549, MCF7, HeLa, and MDA-MB-231 cell lines. PRMT5/EGFR-IN-1 has favorable in vivo PK and PD properties. PRMT5/EGFR-IN-1 can significantly inhibit the growth of MCF7 orthotopic xenograft tumors[1].

• Target Antigen:

  EGFR; Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/prmt5-egfr-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC(C2NCCC3=C2NC4=CC=CC=C43)=CC=C1OCC5=CC(C(F)(F)F)=CC(C(F)(F)F)=C5

• Molecular Weight:

  520.47

• References & Citations:

  [1]Zhang J, et al. Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents. Eur J Med Chem. 2024 Mar 18;269:116341.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported